Director, Global Milvexian and CV Strategy & Operations at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, CardiovascularIndustries

Requirements

BA; MBA or advanced degree preferred
Minimum 8 years of commercial experience in pharmaceutical or other relevant industry
Alliance experience preferred
Ability to think strategically and lead large-scale initiatives
Ability to lead a large cross-functional matrix team of stakeholders—including Commercial, Development, and Clinical—through informal authority and collaborative partnership
Ability to work proactively and independently in a fast moving and increasing complex environment

Responsibilities

Serve as Chief of Staff to VP, Global Milvexian and CV
Oversee Commercial team operating rhythm, including Commercial team meetings, coordination with Brand Working Group, and preparation for leadership reviews
Drive readiness for milvexian CSRE governance meeting, including leading indication sub-teams, 3M readiness, coordination with markets, and project management
Leverage launch excellence roadmap and dashboard to drive G2L handoff with key markets and ensure coordination with J&J partners
Post G2L handoff, drive LCM, global market engagement, and launch tracking for milvexian
Lead CV Strat plan process for Global CV Early Assets and BD team
Ensure operational discipline across teams (Milvexian, Early Assets/Business Development) by tracking progress against key priorities, milestones (eg QBR reviews, quarterly earnings, LTFP)
Support EDs for Milvexian and Early Assets/BD CV and partner with finance to oversee budget planning, projection optimization for overall Global CV budget

Skills

Chief of Staff

Strategy & Operations

Governance Presentations

Project Management

Launch Excellence

Market Engagement

LCM

Commercial Operations

Alliance Management

Leadership Reviews

G2L Handoff

Brand Working Group

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free